Keywords
Last Name
Institution

Jared L Crandon PharmD, BCPS

TitleAssociate Director, Clinical and Experimental Pharmacology
InstitutionHartford Hospital
DepartmentCenter for Anti-Infective Research and Development
Address80 Seymour Street
Phone860-545-1109
Fax860-545-3992
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Ghazi IM, Crandon JL, Lesho EP, McGann P, Nicolau DP. In vivo efficacy of humanized high dose meropenem and comparators against Pseudomonas aeruginosa isolates producing verona integron-encoded metallo-ß-lactamase (VIM). Heliyon. 2016 Jun; 2(6):e00121. PMID: 27441293.
      View in: PubMed
    2. Zmarlicka MT, Cardwell SM, Crandon JL, Nicolau DP, McClure MH, Nailor MD. Evaluation of a disease state management guideline for urinary tract infection. Int J Antimicrob Agents. 2016 Jun; 47(6):451-6. PMID: 27211208.
      View in: PubMed
    3. Cardwell SM, Crandon JL, Nicolau DP, McClure MH, Nailor MD. Epidemiology and economics of adult patients hospitalized with urinary tract infections. Hosp Pract (1995). 2016 Feb; 44(1):33-40. PMID: 26673518.
      View in: PubMed
    4. So W, Crandon JL, Hamada Y, Nicolau DP. Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem. J Antimicrob Chemother. 2016 Feb; 71(2):428-37. PMID: 26559690.
      View in: PubMed
    5. So W, Crandon JL, Nicolau DP. Poor outcomes of empiric ceftriaxone ± azithromycin for community-acquired pneumonia caused by methicillin-susceptible Staphylococcus aureus. Intern Emerg Med. 2016 Jun; 11(4):545-51. PMID: 26531307.
      View in: PubMed
    6. Kim A, Kutschke A, Ehmann DE, Patey SA, Crandon JL, Gorseth E, Miller AA, McLaughlin RE, Blinn CM, Chen A, Nayar AS, Dangel B, Tsai AS, Rooney MT, Murphy-Benenato KE, Eakin AE, Nicolau DP. Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated Efficacy. Antimicrob Agents Chemother. 2015 Dec; 59(12):7743-52. PMID: 26438502.
      View in: PubMed
    7. Ghazi IM, Crandon JL, Lesho EP, McGann P, Nicolau DP. Efficacy of Humanized High-Dose Meropenem, Cefepime, and Levofloxacin against Enterobacteriaceae Isolates Producing Verona Integron-Encoded Metallo-ß-Lactamase (VIM) in a Murine Thigh Infection Model. Antimicrob Agents Chemother. 2015 Nov; 59(11):7145-7. PMID: 26416855; PMCID: PMC4604359 [Available on 05/01/16].
    8. Crandon JL, Nicolau DP. In Vitro Activity of Cefepime/AAI101 and Comparators against Cefepime Non-susceptible Enterobacteriaceae. Pathogens. 2015; 4(3):620-5. PMID: 26295262; PMCID: PMC4584277.
    9. O'Dowd H, Shannon DE, Chandupatla KR, Dixit V, Engtrakul JJ, Ye Z, Jones SM, O'Brien CF, Nicolau DP, Tessier PR, Crandon JL, Song B, Macikenas D, Hanzelka BL, Le Tiran A, Bennani YL, Charifson PS, Grillot AL. Discovery and Characterization of a Water-Soluble Prodrug of a Dual Inhibitor of Bacterial DNA Gyrase and Topoisomerase IV. ACS Med Chem Lett. 2015 Jul 9; 6(7):822-6. PMID: 26191374; PMCID: PMC4499827 [Available on 07/09/16].
    10. So W, Crandon JL, Nicolau DP. Pharmacodynamic Profile of GSK2140944 against Methicillin-Resistant Staphylococcus aureus in a Murine Lung Infection Model. Antimicrob Agents Chemother. 2015 Aug; 59(8):4956-61. PMID: 26055376; PMCID: PMC4505212 [Available on 02/01/16].
    11. Crandon JL, Nicolau DP. In vivo activities of simulated human doses of cefepime and cefepime-AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae. Antimicrob Agents Chemother. 2015 May; 59(5):2688-94. PMID: 25712356; PMCID: PMC4394792.
    12. So W, Crandon JL, Nicolau DP. Effects of Urine Matrix and pH on the Potency of Delafloxacin and Ciprofloxacin against Urogenic Escherichia coli and Klebsiella pneumoniae. J Urol. 2015 Aug; 194(2):563-70. PMID: 25637857.
      View in: PubMed
    13. Tomaras AP, Crandon JL, McPherson CJ, Nicolau DP. Potentiation of antibacterial activity of the MB-1 siderophore-monobactam conjugate using an efflux pump inhibitor. Antimicrob Agents Chemother. 2015 Apr; 59(4):2439-42. PMID: 25605364; PMCID: PMC4356814.
    14. Thabit AK, Crandon JL, Nicolau DP. Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials. Expert Opin Pharmacother. 2015 Feb; 16(2):159-77. PMID: 25496207.
      View in: PubMed
    15. Bhalodi AA, Crandon JL, Williams G, Nicolau DP. Supporting the ceftaroline fosamil/avibactam Enterobacteriaceae breakpoint determination using humanised in vivo exposures in a thigh model. Int J Antimicrob Agents. 2014 Dec; 44(6):508-13. PMID: 25278330.
      View in: PubMed
    16. MacVane SH, Crandon JL, Nichols WW, Nicolau DP. In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates. Antimicrob Agents Chemother. 2014 Nov; 58(11):6913-9. PMID: 25223999; PMCID: PMC4249385.
    17. MacVane SH, Crandon JL, Nichols WW, Nicolau DP. Unexpected in vivo activity of ceftazidime alone and in combination with avibactam against New Delhi metallo-ß-lactamase-producing Enterobacteriaceae in a murine thigh infection model. Antimicrob Agents Chemother. 2014 Nov; 58(11):7007-9. PMID: 25223998; PMCID: PMC4249434.
    18. So W, Crandon JL, Zhanel GG, Nicolau DP. Comparison of in vivo and in vitro pharmacodynamics of a humanized regimen of 600 milligrams of Ceftaroline Fosamil every 12 hours against Staphylococcus aureus at initial inocula of 106 and 108 CFU per milliliter. Antimicrob Agents Chemother. 2014 Nov; 58(11):6931-3. PMID: 25136006; PMCID: PMC4249378.
    19. Wiskirchen DE, Nordmann P, Crandon JL, Nicolau DP. In vivo efficacy of human simulated regimens of carbapenems and comparator agents against NDM-1-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2014; 58(3):1671-7. PMID: 24379195; PMCID: PMC3957895.
    20. Wiskirchen DE, Nordmann P, Crandon JL, Nicolau DP. Efficacy of humanized carbapenem and ceftazidime regimens against Enterobacteriaceae producing OXA-48 carbapenemase in a murine infection model. Antimicrob Agents Chemother. 2014; 58(3):1678-83. PMID: 24379200; PMCID: PMC3957853.
    21. Housman ST, Crandon JL, Nichols WW, Nicolau DP. Efficacies of ceftazidime-avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model. Antimicrob Agents Chemother. 2014; 58(3):1365-71. PMID: 24342641; PMCID: PMC3957844.
    22. Macvane SH, Crandon JL, Nicolau DP. Characterizing in vivo pharmacodynamics of carbapenems against Acinetobacter baumannii in a murine thigh infection model to support breakpoint determinations. Antimicrob Agents Chemother. 2014; 58(1):599-601. PMID: 24165174; PMCID: PMC3910748.
    23. Schuetz AN, Brasso WB, Crandon JL, Hardy DJ, Jenkins SG, Jones RN, Knapp CC, Reller LB. Cefazolin as a class representative for oral cephalosporins and uncomplicated urinary tract infections caused by indicated Enterobacteriaceae. Diagn Microbiol Infect Dis. 2013 Dec; 77(4):381-2. PMID: 24091106.
      View in: PubMed
    24. Bhalodi AA, Crandon JL, Williams G, Nicolau DP. In vivo efficacy of humanized ceftaroline fosamil-avibactam exposures in a polymicrobial infection model. Antimicrob Agents Chemother. 2013 Nov; 57(11):5674-8. PMID: 24041891; PMCID: PMC3811285.
    25. Crandon JL, MacVane SH, Nicolau DP. Clinical laboratory-based assay methodologies may underestimate and increase variability of vancomycin protein binding in hospitalized patients. Pharmacotherapy. 2014 Feb; 34(2):203-9. PMID: 23798336.
      View in: PubMed
    26. Magee TV, Brown MF, Starr JT, Ackley DC, Abramite JA, Aubrecht J, Butler A, Crandon JL, Dib-Hajj F, Flanagan ME, Granskog K, Hardink JR, Huband MD, Irvine R, Kuhn M, Leach KL, Li B, Lin J, Luke DR, MacVane SH, Miller AA, McCurdy S, McKim JM, Nicolau DP, Nguyen TT, Noe MC, O'Donnell JP, Seibel SB, Shen Y, Stepan AF, Tomaras AP, Wilga PC, Zhang L, Xu J, Chen JM. Discovery of Dap-3 polymyxin analogues for the treatment of multidrug-resistant Gram-negative nosocomial infections. J Med Chem. 2013 Jun 27; 56(12):5079-93. PMID: 23735048.
      View in: PubMed
    27. Tomaras AP, Crandon JL, McPherson CJ, Banevicius MA, Finegan SM, Irvine RL, Brown MF, O'Donnell JP, Nicolau DP. Adaptation-based resistance to siderophore-conjugated antibacterial agents by Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2013 Sep; 57(9):4197-207. PMID: 23774440; PMCID: PMC3754284.
    28. Wiskirchen DE, Nordmann P, Crandon JL, Nicolau DP. Efficacy of humanized carbapenem exposures against New Delhi metallo-ß-lactamase (NDM-1)-producing enterobacteriaceae in a murine infection model. Antimicrob Agents Chemother. 2013 Aug; 57(8):3936-40. PMID: 23733463; PMCID: PMC3719754.
    29. Crandon JL, Nicolau DP. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-ß-lactamase producers. Antimicrob Agents Chemother. 2013 Jul; 57(7):3299-306. PMID: 23650162; PMCID: PMC3697389.
    30. Wiskirchen DE, Crandon JL, Nicolau DP. Impact of various conditions on the efficacy of dual carbapenem therapy against KPC-producing Klebsiella pneumoniae. Int J Antimicrob Agents. 2013 Jun; 41(6):582-5. PMID: 23611306.
      View in: PubMed
    31. Hagihara M, Crandon JL, Urban C, Nicolau DP. Efficacy of doripenem and ertapenem against KPC-2-producing and non-KPC-producing Klebsiella pneumoniae with similar MICs. J Antimicrob Chemother. 2013 Jul; 68(7):1616-8. PMID: 23475648.
      View in: PubMed
    32. Lamb LM, Crandon JL, Nicolau DP. Pharmacokinetic and pharmacodynamic evaluation of P-873 versus Klebsiella pneumoniae in a neutropenic murine thigh infection model. Antimicrob Agents Chemother. 2013 Apr; 57(4):1971-3. PMID: 23357768; PMCID: PMC3623370.
    33. Hagihara M, Crandon JL, Urban CM, Nicolau DP. KPC presence in Pseudomonas aeruginosa has minimal impact on the in vivo efficacy of carbapenem therapy. Antimicrob Agents Chemother. 2013 Feb; 57(2):1086-8. PMID: 23254422; PMCID: PMC3553679.
    34. Crandon JL, Schuck VJ, Banevicius MA, Beaudoin ME, Nichols WW, Tanudra MA, Nicolau DP. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2012 Dec; 56(12):6137-46. PMID: 22985878; PMCID: PMC3497209.
    35. Bhalodi AA, Crandon JL, Biek D, Nicolau DP. Efficacy of ceftaroline fosamil in a staphylococcal murine pneumonia model. Antimicrob Agents Chemother. 2012 Dec; 56(12):6160-5. PMID: 22985880; PMCID: PMC3497181.
    36. Keel RA, Tessier PR, Crandon JL, Nicolau DP. Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model. Antimicrob Agents Chemother. 2012 Aug; 56(8):4403-7. PMID: 22687504; PMCID: PMC3421595.
    37. Keel RA, Crandon JL, Nicolau DP. Pharmacokinetics and pulmonary disposition of tedizolid and linezolid in a murine pneumonia model under variable conditions. Antimicrob Agents Chemother. 2012 Jun; 56(6):3420-2. PMID: 22430966; PMCID: PMC3370766.
    38. Tessier PR, Keel RA, Hagihara M, Crandon JL, Nicolau DP. Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model. Antimicrob Agents Chemother. 2012 May; 56(5):2342-6. PMID: 22354302; PMCID: PMC3346598.
    39. Hagihara M, Crandon JL, Nicolau DP. The efficacy and safety of antibiotic combination therapy for infections caused by Gram-positive and Gram-negative organisms. Expert Opin Drug Saf. 2012 Mar; 11(2):221-33. PMID: 22074343.
      View in: PubMed
    40. Housman ST, Keel RA, Crandon JL, Williams G, Nicolau DP. Efficacy of human simulated exposures of ceftaroline against phenotypically diverse Enterobacteriaceae isolates. Antimicrob Agents Chemother. 2012 May; 56(5):2576-80. PMID: 22330908; PMCID: PMC3346611.
    41. Keel RA, Crandon JL, Nicolau DP. Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2011 Sep; 55(9):4028-32. PMID: 21670184; PMCID: PMC3165327.
    42. Wiskirchen DE, Crandon JL, Furtado GH, Williams G, Nicolau DP. In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2011 Jul; 55(7):3220-5. PMID: 21518838; PMCID: PMC3122417.
    43. Crandon JL, Nicolau DP. Pharmacodynamic approaches to optimizing beta-lactam therapy. Crit Care Clin. 2011 Jan; 27(1):77-93. PMID: 21144987.
      View in: PubMed
    44. Crandon JL, Ariano RE, Zelenitsky SA, Nicasio AM, Kuti JL, Nicolau DP. Optimization of meropenem dosage in the critically ill population based on renal function. Intensive Care Med. 2011 Apr; 37(4):632-8. PMID: 21136037.
      View in: PubMed
    45. Crandon JL, Sutherland C, Nicolau DP. Stability of doripenem in polyvinyl chloride bags and elastomeric pumps. Am J Health Syst Pharm. 2010 Sep 15; 67(18):1539-44. PMID: 20811032.
      View in: PubMed
    46. Crandon JL, Kuti JL, Nicolau DP. Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model. Antimicrob Agents Chemother. 2010 Dec; 54(12):5115-9. PMID: 20837760; PMCID: PMC2981287.
    47. Keel RA, Sutherland CA, Crandon JL, Nicolau DP. Stability of doripenem, imipenem and meropenem at elevated room temperatures. Int J Antimicrob Agents. 2011 Feb; 37(2):184-5. PMID: 20702066.
      View in: PubMed
    48. Crandon JL, Bulik CC, Kuti JL, Nicolau DP. Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010 Mar; 54(3):1111-6. PMID: 20038614; PMCID: PMC2825990.
    49. Koomanachai P, Crandon JL, Nicolau DP. Newer developments in the treatment of Gram-positive infections. Expert Opin Pharmacother. 2009 Dec; 10(17):2829-43. PMID: 19929705.
      View in: PubMed
    50. Crandon JL, Bulik CC, Nicolau DP. In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009 Oct; 53(10):4352-6. PMID: 19770286; PMCID: PMC2764160.
    51. Crandon JL, Banevicius MA, Fang AF, Crownover PH, Knauft RF, Pope JS, Russomanno JH, Shore E, Nicolau DP, Kuti JL. Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. Antimicrob Agents Chemother. 2009 Dec; 53(12):5102-7. PMID: 19770284; PMCID: PMC2786330.
    52. Koomanachai P, Crandon JL, Banevicius MA, Peng L, Nicolau DP. Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model. Antimicrob Agents Chemother. 2009 Dec; 53(12):5060-3. PMID: 19738006; PMCID: PMC2786358.
    53. Crandon JL, Kim A, Nicolau DP. Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs. J Antimicrob Chemother. 2009 Oct; 64(4):837-9. PMID: 19696049.
      View in: PubMed
    54. Nicasio AM, Crandon JL, Nicolau DP. In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother. 2009 Jul; 53(7):2756-61. PMID: 19364850; PMCID: PMC2704680.
    55. Crandon JL, Kuti JL, Jones RN, Nicolau DP. Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance. Ann Pharmacother. 2009 Feb; 43(2):220-7. PMID: 19193582.
      View in: PubMed
    56. Nicasio AM, Ariano RE, Zelenitsky SA, Kim A, Crandon JL, Kuti JL, Nicolau DP. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother. 2009 Apr; 53(4):1476-81. PMID: 19188394; PMCID: PMC2663089.
    57. Crandon JL, Banevicius MA, Nicolau DP. Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. Antimicrob Agents Chemother. 2009 Mar; 53(3):1165-9. PMID: 19114676; PMCID: PMC2650523.
    58. Koomanachai P, Crandon JL, Kuti JL, Nicolau DP. Comparative pharmacodynamics for intravenous antibiotics against Gram-negative bacteria in Europe between 2002 and 2006: a report from the OPTAMA program. Int J Antimicrob Agents. 2009 Apr; 33(4):348-53. PMID: 19091515.
      View in: PubMed
    59. Crandon J, Nicolau DP. Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens. Future Microbiol. 2008 Jun; 3(3):251-63. PMID: 18505390.
      View in: PubMed
    Crandon's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _